<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240521180807&amp;fc=20230708114047&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240521180807&amp;fc=20230708114047&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 21 May 2024 22:08:08 +0000</lastbuilddate>
<pubDate>Tue, 21 May 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>The grey areas in anticoagulation for stroke prevention and a focus on chronic stress in carotid atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38770965/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 21;45(19):1687-1691. doi: 10.1093/eurheartj/ehae285.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38770965/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38770965</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae285>10.1093/eurheartj/ehae285</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38770965</guid>
<pubDate>Tue, 21 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-05-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The grey areas in anticoagulation for stroke prevention and a focus on chronic stress in carotid atherosclerosis</dc:title>
<dc:identifier>pmid:38770965</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae285</dc:identifier>
</item>
<item>
<title>Cortico-limbic restructuring and atherosclerosis: a stressful liaison</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38770964/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 21;45(19):1765-1767. doi: 10.1093/eurheartj/ehae212.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38770964/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38770964</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae212>10.1093/eurheartj/ehae212</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38770964</guid>
<pubDate>Tue, 21 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Sarajo K Mohanta</dc:creator>
<dc:creator>Donato Santovito</dc:creator>
<dc:creator>Christian Weber</dc:creator>
<dc:date>2024-05-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cortico-limbic restructuring and atherosclerosis: a stressful liaison</dc:title>
<dc:identifier>pmid:38770964</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae212</dc:identifier>
</item>
<item>
<title>3D Imaging Reveals Complex Microvascular Remodeling in the Right Ventricle in Pulmonary Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38770652/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: 3D deep tissue imaging of the failing RV in PAB mice, pulmonary hypertension rats, and patients with pulmonary arterial hypertension reveals complex microvascular changes to preserve the microvascular density and maintain a stable microvascular-cardiomyocyte contact. Our studies provide a novel framework to understand microvascular adaptation in the pressure-overloaded RV that focuses on cell-cell interaction and goes beyond the concept of capillary rarefaction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 May 21. doi: 10.1161/CIRCRESAHA.123.323546. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Pathogenic concepts of right ventricular (RV) failure in pulmonary arterial hypertension focus on a critical loss of microvasculature. However, the methods underpinning prior studies did not take into account the 3-dimensional (3D) aspects of cardiac tissue, making accurate quantification difficult. We applied deep-tissue imaging to the pressure-overloaded RV to uncover the 3D properties of the microvascular network and determine whether deficient microvascular adaptation contributes to RV failure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Heart sections measuring 250-µm-thick were obtained from mice after pulmonary artery banding (PAB) or debanding PAB surgery and properties of the RV microvascular network were assessed using 3D imaging and quantification. Human heart tissues harvested at the time of transplantation from pulmonary arterial hypertension cases were compared with tissues from control cases with normal RV function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Longitudinal 3D assessment of PAB mouse hearts uncovered complex microvascular remodeling characterized by tortuous, shorter, thicker, highly branched vessels, and overall preserved microvascular density. This remodeling process was reversible in debanding PAB mice in which the RV function recovers over time. The remodeled microvasculature tightly wrapped around the hypertrophied cardiomyocytes to maintain a stable contact surface to cardiomyocytes as an adaptation to RV pressure overload, even in end-stage RV failure. However, microvasculature-cardiomyocyte contact was impaired in areas with interstitial fibrosis where cardiomyocytes displayed signs of hypoxia. Similar to PAB animals, microvascular density in the RV was preserved in patients with end-stage pulmonary arterial hypertension, and microvascular architectural changes appeared to vary by etiology, with patients with pulmonary veno-occlusive disease displaying a lack of microvascular complexity with uniformly short segments.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: 3D deep tissue imaging of the failing RV in PAB mice, pulmonary hypertension rats, and patients with pulmonary arterial hypertension reveals complex microvascular changes to preserve the microvascular density and maintain a stable microvascular-cardiomyocyte contact. Our studies provide a novel framework to understand microvascular adaptation in the pressure-overloaded RV that focuses on cell-cell interaction and goes beyond the concept of capillary rarefaction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38770652/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38770652</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323546>10.1161/CIRCRESAHA.123.323546</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38770652</guid>
<pubDate>Tue, 21 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Kenzo Ichimura</dc:creator>
<dc:creator>Mario Boehm</dc:creator>
<dc:creator>Adam M Andruska</dc:creator>
<dc:creator>Fan Zhang</dc:creator>
<dc:creator>Katharina Schimmel</dc:creator>
<dc:creator>Spencer Bonham</dc:creator>
<dc:creator>Angela Kabiri</dc:creator>
<dc:creator>Vitaly O Kheyfets</dc:creator>
<dc:creator>Shoko Ichimura</dc:creator>
<dc:creator>Sushma Reddy</dc:creator>
<dc:creator>Yuqiang Mao</dc:creator>
<dc:creator>Tianyi Zhang</dc:creator>
<dc:creator>Gordon Wang</dc:creator>
<dc:creator>Everton J Santana</dc:creator>
<dc:creator>Xuefei Tian</dc:creator>
<dc:creator>Ilham Essafri</dc:creator>
<dc:creator>Ryan Vinh</dc:creator>
<dc:creator>Wen Tian</dc:creator>
<dc:creator>Mark R Nicolls</dc:creator>
<dc:creator>Shin Yajima</dc:creator>
<dc:creator>Yasuhiro Shudo</dc:creator>
<dc:creator>John W MacArthur</dc:creator>
<dc:creator>Y Joseph Woo</dc:creator>
<dc:creator>Ross J Metzger</dc:creator>
<dc:creator>Edda Spiekerkoetter</dc:creator>
<dc:date>2024-05-21</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>3D Imaging Reveals Complex Microvascular Remodeling in the Right Ventricle in Pulmonary Hypertension</dc:title>
<dc:identifier>pmid:38770652</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323546</dc:identifier>
</item>
<item>
<title>SMYD2-Methylated PPARγ Facilitates Hypoxia-Induced Pulmonary Hypertension by Activating Mitophagy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38770649/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our results demonstrated that SMYD2 monomethylates nonhistone PPARγ and inhibits its nuclear translocation and activation to accelerate PASMC proliferation and PH by triggering mitophagy, indicating that targeting SMYD2 or activating PPARγ are potential strategies for the prevention of PH.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 May 21. doi: 10.1161/CIRCRESAHA.124.323698. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Hyperproliferation of pulmonary arterial smooth muscle cells (PASMCs) and consequent pulmonary vascular remodeling are the crucial pathological features of pulmonary hypertension (PH). Protein methylation has been shown to be critically involved in PASMC proliferation and PH, but the underlying mechanism remains largely unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: PH animal models were generated by treating mice/rats with chronic hypoxia for 4 weeks. SMYD2-vTg mice (vascular smooth muscle cell-specific suppressor of variegation, enhancer of zeste, trithorax and myeloid Nervy DEAF-1 domain-containing protein 2 transgenic) or wild-type rats and mice treated with LLY-507 were used to investigate the function of SMYD2 (suppressor of variegation, enhancer of zeste, trithorax and myeloid Nervy DEAF-1 domain-containing protein 2) on PH development in vivo. Primary cultured rat PASMCs with SMYD2 knockdown or overexpression were used to explore the effects of SMYD2 on proliferation and to decipher the underlying mechanism.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We demonstrated that the expression of the lysine methyltransferase SMYD2 was upregulated in the smooth muscle cells of pulmonary arteries from patients with PH and hypoxia-exposed rats/mice and in the cytoplasm of hypoxia-induced rat PASMCs. More importantly, targeted inhibition of SMYD2 by LLY-507 significantly attenuated hypoxia-induced pulmonary vascular remodeling and PH development in both male and female rats in vivo and reduced rat PASMC hyperproliferation in vitro. In contrast, SMYD2-vTg mice exhibited more severe PH phenotypes and related pathological changes than nontransgenic mice after 4 weeks of chronic hypoxia treatment. Furthermore, SMYD2 overexpression promoted, while SMYD2 knockdown suppressed, the proliferation of rat PASMCs by affecting the cell cycle checkpoint between S and G2 phases. Mechanistically, we revealed that SMYD2 directly interacted with and monomethylated PPARγ (peroxisome proliferator-activated receptor gamma) to inhibit the nuclear translocation and transcriptional activity of PPARγ, which further promoted mitophagy to facilitate PASMC proliferation and PH development. Furthermore, rosiglitazone, a PPARγ agonist, largely abolished the detrimental effects of SMYD2 overexpression on PASMC proliferation and PH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results demonstrated that SMYD2 monomethylates nonhistone PPARγ and inhibits its nuclear translocation and activation to accelerate PASMC proliferation and PH by triggering mitophagy, indicating that targeting SMYD2 or activating PPARγ are potential strategies for the prevention of PH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38770649/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38770649</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.323698>10.1161/CIRCRESAHA.124.323698</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38770649</guid>
<pubDate>Tue, 21 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Yi Li</dc:creator>
<dc:creator>Xiang Wei</dc:creator>
<dc:creator>Rui Xiao</dc:creator>
<dc:creator>YongJie Chen</dc:creator>
<dc:creator>Xiong Tianxin</dc:creator>
<dc:creator>Ze-Min Fang</dc:creator>
<dc:creator>Bo Huo</dc:creator>
<dc:creator>Xian Guo</dc:creator>
<dc:creator>Hanshen Luo</dc:creator>
<dc:creator>Xingliang Wu</dc:creator>
<dc:creator>Liyuan Liu</dc:creator>
<dc:creator>Xue-Hai Zhu</dc:creator>
<dc:creator>Qinghua Hu</dc:creator>
<dc:creator>Ding-Sheng Jiang</dc:creator>
<dc:creator>Xin Yi</dc:creator>
<dc:date>2024-05-21</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>SMYD2-Methylated PPARγ Facilitates Hypoxia-Induced Pulmonary Hypertension by Activating Mitophagy</dc:title>
<dc:identifier>pmid:38770649</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.323698</dc:identifier>
</item>
<item>
<title>Bile acid receptor protects against diabetic cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38769466/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 May 20. doi: 10.1038/s41569-024-01040-y. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38769466/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38769466</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01040-y>10.1038/s41569-024-01040-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38769466</guid>
<pubDate>Mon, 20 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2024-05-20</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Bile acid receptor protects against diabetic cardiomyopathy</dc:title>
<dc:identifier>pmid:38769466</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01040-y</dc:identifier>
</item>
<item>
<title>Nocturnal heat exposure and stroke risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38768958/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study found nocturnal heat exposure to be related to elevated stroke risk after controlling for maximum daytime temperature, with increasing susceptibility between 2006 and 2020. These results underscore the importance of considering nocturnal heat as a critical trigger of stroke events in a warming climate.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 21:ehae277. doi: 10.1093/eurheartj/ehae277. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: In recent decades, nighttime temperatures have increased faster than daytime temperatures. The increasing prevalence of nocturnal heat exposure may pose a significant risk to cardiovascular health. This study investigated the association between nighttime heat exposure and stroke risk in the region of Augsburg, Germany, and examined its temporal variations over 15 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Hourly meteorological parameters, including mean temperature, relative humidity, and barometric pressure, were acquired from a local meteorological station. A data set was obtained consisting of 11 037 clinical stroke cases diagnosed during warmer months (May to October) between the years 2006 and 2020. The average age of cases was 71.3 years. Among these cases, 642 were identified as haemorrhagic strokes, 7430 were classified as ischaemic strokes, and 2947 were transient ischaemic attacks. A time-stratified case-crossover analysis with a distributed lag non-linear model was used to estimate the stroke risk associated with extreme nighttime heat, as measured by the hot night excess (HNE) index after controlling for the potential confounding effects of daily maximum temperature and other climatic variables. Subgroup analyses by age group, sex, stroke subtype, and stroke severity were performed to identify variations in susceptibility to nighttime heat.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Results suggested a significant increase in stroke risk on days with extreme nighttime heat (97.5% percentile of HNE) (odds ratio 1.07, 95% confidence interval 1.01-1.15) during the full study period. When comparing the results for 2013-20 with the results for 2006-12, there was a significant increase (P &lt; .05) in HNE-related risk for all strokes and specifically for ischaemic strokes during the more recent period. Furthermore, older individuals, females, and patients with mild stroke symptoms exhibited a significantly increased vulnerability to nighttime heat.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study found nocturnal heat exposure to be related to elevated stroke risk after controlling for maximum daytime temperature, with increasing susceptibility between 2006 and 2020. These results underscore the importance of considering nocturnal heat as a critical trigger of stroke events in a warming climate.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38768958/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38768958</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae277>10.1093/eurheartj/ehae277</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38768958</guid>
<pubDate>Mon, 20 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Cheng He</dc:creator>
<dc:creator>Susanne Breitner</dc:creator>
<dc:creator>Siqi Zhang</dc:creator>
<dc:creator>Veronika Huber</dc:creator>
<dc:creator>Markus Naumann</dc:creator>
<dc:creator>Claudia Traidl-Hoffmann</dc:creator>
<dc:creator>Gertrud Hammel</dc:creator>
<dc:creator>Annette Peters</dc:creator>
<dc:creator>Michael Ertl</dc:creator>
<dc:creator>Alexandra Schneider</dc:creator>
<dc:date>2024-05-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Nocturnal heat exposure and stroke risk</dc:title>
<dc:identifier>pmid:38768958</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae277</dc:identifier>
</item>
<item>
<title>Correction to: 2022 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Support; Education, Implementation, and Teams; and First Aid Task Forces</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38768278/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 21;149(21):e1218. doi: 10.1161/CIR.0000000000001253. Epub 2024 May 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38768278/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38768278</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001253>10.1161/CIR.0000000000001253</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38768278</guid>
<pubDate>Mon, 20 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2022 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Support; Education, Implementation, and Teams; and First Aid Task Forces</dc:title>
<dc:identifier>pmid:38768278</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001253</dc:identifier>
</item>
<item>
<title>Correction to: Organ Donation After Out-of-Hospital Cardiac Arrest: A Scientific Statement From the International Liaison Committee on Resuscitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38768277/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 21;149(21):e1217. doi: 10.1161/CIR.0000000000001252. Epub 2024 May 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38768277/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38768277</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001252>10.1161/CIR.0000000000001252</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38768277</guid>
<pubDate>Mon, 20 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Organ Donation After Out-of-Hospital Cardiac Arrest: A Scientific Statement From the International Liaison Committee on Resuscitation</dc:title>
<dc:identifier>pmid:38768277</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001252</dc:identifier>
</item>
<item>
<title>Leveraging Human Tissue for Discovery in Heart Transplantation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38768276/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 21;149(21):1667-1669. doi: 10.1161/CIRCULATIONAHA.124.068884. Epub 2024 May 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38768276/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38768276</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068884>10.1161/CIRCULATIONAHA.124.068884</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38768276</guid>
<pubDate>Mon, 20 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Kory Lavine</dc:creator>
<dc:date>2024-05-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Leveraging Human Tissue for Discovery in Heart Transplantation</dc:title>
<dc:identifier>pmid:38768276</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068884</dc:identifier>
</item>
<item>
<title>Letter by Chen et al Regarding Article, "Reduced Mitochondrial Protein Translation Promotes Cardiomyocyte Proliferation and Heart Regeneration"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38768275/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 21;149(21):e1194. doi: 10.1161/CIRCULATIONAHA.123.068129. Epub 2024 May 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38768275/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38768275</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068129>10.1161/CIRCULATIONAHA.123.068129</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38768275</guid>
<pubDate>Mon, 20 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Yunan Chen</dc:creator>
<dc:creator>Sixiang Lin</dc:creator>
<dc:creator>Mingge Ding</dc:creator>
<dc:date>2024-05-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Chen et al Regarding Article, "Reduced Mitochondrial Protein Translation Promotes Cardiomyocyte Proliferation and Heart Regeneration"</dc:title>
<dc:identifier>pmid:38768275</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068129</dc:identifier>
</item>
<item>
<title>Detection of Circulating Transthyretin Amyloid Aggregates in Plasma: A Novel Biomarker for Transthyretin Amyloidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38768274/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 21;149(21):1696-1699. doi: 10.1161/CIRCULATIONAHA.123.067225. Epub 2024 May 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38768274/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38768274</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11107565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">PMC11107565</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067225>10.1161/CIRCULATIONAHA.123.067225</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38768274</guid>
<pubDate>Mon, 20 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Rose Pedretti</dc:creator>
<dc:creator>Lanie Wang</dc:creator>
<dc:creator>Mazen Hanna</dc:creator>
<dc:creator>Merrill D Benson</dc:creator>
<dc:creator>Justin L Grodin</dc:creator>
<dc:creator>W H Wilson Tang</dc:creator>
<dc:creator>Ahmad Masri</dc:creator>
<dc:creator>Lorena Saelices</dc:creator>
<dc:date>2024-05-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Detection of Circulating Transthyretin Amyloid Aggregates in Plasma: A Novel Biomarker for Transthyretin Amyloidosis</dc:title>
<dc:identifier>pmid:38768274</dc:identifier>
<dc:identifier>pmc:PMC11107565</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067225</dc:identifier>
</item>
<item>
<title>Type 1 Brugada Pattern May Be Provoked by Ajmaline in Some Healthy Subjects: Results From a Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38768273/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 21;149(21):1693-1695. doi: 10.1161/CIRCULATIONAHA.123.067223. Epub 2024 May 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38768273/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38768273</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067223>10.1161/CIRCULATIONAHA.123.067223</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38768273</guid>
<pubDate>Mon, 20 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Bode Ensam</dc:creator>
<dc:creator>Chiara Scrocco</dc:creator>
<dc:creator>David Johnson</dc:creator>
<dc:creator>Yanushi D Wijeyeratne</dc:creator>
<dc:creator>Rachel Bastiaenen</dc:creator>
<dc:creator>Belinda Gray</dc:creator>
<dc:creator>Chris Miles</dc:creator>
<dc:creator>Yael Ben-Haim</dc:creator>
<dc:creator>Stathis Papatheodorou</dc:creator>
<dc:creator>Sanjay Sharma</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:creator>Brian Devine</dc:creator>
<dc:creator>Peter W Macfarlane</dc:creator>
<dc:creator>Elijah R Behr</dc:creator>
<dc:date>2024-05-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Type 1 Brugada Pattern May Be Provoked by Ajmaline in Some Healthy Subjects: Results From a Clinical Trial</dc:title>
<dc:identifier>pmid:38768273</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067223</dc:identifier>
</item>
<item>
<title>Obesity and Cardiovascular Disease: A New Dawn</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38768272/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 21;149(21):1621-1623. doi: 10.1161/CIRCULATIONAHA.123.065485. Epub 2024 May 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38768272/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38768272</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065485>10.1161/CIRCULATIONAHA.123.065485</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38768272</guid>
<pubDate>Mon, 20 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Naveed Sattar</dc:creator>
<dc:creator>Ian J Neeland</dc:creator>
<dc:creator>Darren K McGuire</dc:creator>
<dc:date>2024-05-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Obesity and Cardiovascular Disease: A New Dawn</dc:title>
<dc:identifier>pmid:38768272</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065485</dc:identifier>
</item>
<item>
<title>Response by Gao et al to Letter Regarding Article, "Reduced Mitochondrial Protein Translation Promotes Cardiomyocyte Proliferation and Heart Regeneration"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38768271/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 21;149(21):e1195-e1196. doi: 10.1161/CIRCULATIONAHA.124.069377. Epub 2024 May 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38768271/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38768271</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11107564/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">PMC11107564</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069377>10.1161/CIRCULATIONAHA.124.069377</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38768271</guid>
<pubDate>Mon, 20 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Feng Gao</dc:creator>
<dc:creator>John D Mably</dc:creator>
<dc:creator>Da-Zhi Wang</dc:creator>
<dc:creator>Jinghai Chen</dc:creator>
<dc:date>2024-05-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Gao et al to Letter Regarding Article, "Reduced Mitochondrial Protein Translation Promotes Cardiomyocyte Proliferation and Heart Regeneration"</dc:title>
<dc:identifier>pmid:38768271</dc:identifier>
<dc:identifier>pmc:PMC11107564</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069377</dc:identifier>
</item>
<item>
<title>Pursuing P Waves</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38768270/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 21;149(21):1689-1692. doi: 10.1161/CIRCULATIONAHA.124.068680. Epub 2024 May 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38768270/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38768270</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068680>10.1161/CIRCULATIONAHA.124.068680</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38768270</guid>
<pubDate>Mon, 20 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Bharath Peddibhotla</dc:creator>
<dc:creator>Kenneth A Ellenbogen</dc:creator>
<dc:creator>Ajay Pillai</dc:creator>
<dc:date>2024-05-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Pursuing P Waves</dc:title>
<dc:identifier>pmid:38768270</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068680</dc:identifier>
</item>
<item>
<title>Ceramides and Atherosclerotic Cardiovascular Disease: A Current Perspective</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38768269/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 21;149(21):1624-1626. doi: 10.1161/CIRCULATIONAHA.123.065409. Epub 2024 May 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38768269/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38768269</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11107566/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">PMC11107566</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065409>10.1161/CIRCULATIONAHA.123.065409</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38768269</guid>
<pubDate>Mon, 20 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Qingzhang Zhu</dc:creator>
<dc:creator>Philipp E Scherer</dc:creator>
<dc:date>2024-05-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Ceramides and Atherosclerotic Cardiovascular Disease: A Current Perspective</dc:title>
<dc:identifier>pmid:38768269</dc:identifier>
<dc:identifier>pmc:PMC11107566</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065409</dc:identifier>
</item>
<item>
<title>Implementation of Obesity Science Into Clinical Practice: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38766861/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>Obesity is a recognized public health epidemic with a prevalence that continues to increase dramatically in nearly all populations, impeding progress in reducing incidence rates of cardiovascular disease. Over the past decade, obesity science has evolved to improve knowledge of its multifactorial causes, identifying important biological causes and sociological determinants of obesity. Treatments for obesity have also continued to develop, with more evidence-based programs for lifestyle...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 20. doi: 10.1161/CIR.0000000000001221. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Obesity is a recognized public health epidemic with a prevalence that continues to increase dramatically in nearly all populations, impeding progress in reducing incidence rates of cardiovascular disease. Over the past decade, obesity science has evolved to improve knowledge of its multifactorial causes, identifying important biological causes and sociological determinants of obesity. Treatments for obesity have also continued to develop, with more evidence-based programs for lifestyle modification, new pharmacotherapies, and robust data to support bariatric surgery. Despite these advancements, there continues to be a substantial gap between the scientific evidence and the implementation of research into clinical practice for effective obesity management. Addressing barriers to obesity science implementation requires adopting feasible methodologies and targeting multiple levels (eg, clinician, community, system, policy) to facilitate the delivery of obesity-targeted therapies and maximize the effectiveness of guideline-driven care to at-need patient populations. This scientific statement (1) describes strategies shown to be effective or promising for enhancing translation and clinical application of obesity-based research; (2) identifies key gaps in the implementation of obesity science into clinical practice; and (3) provides guidance and resources for health care professionals, health care systems, and other stakeholders to promote broader implementation and uptake of obesity science for improved population-level obesity management. In addition, advances in implementation science that hold promise to bridge the know-do gap in obesity prevention and treatment are discussed. Last, this scientific statement highlights implications for health research policy and future research to improve patient care models and optimize the delivery and sustainability of equitable obesity-related care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38766861/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38766861</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001221>10.1161/CIR.0000000000001221</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38766861</guid>
<pubDate>Mon, 20 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Deepika Laddu</dc:creator>
<dc:creator>Ian J Neeland</dc:creator>
<dc:creator>Mercedes Carnethon</dc:creator>
<dc:creator>Fatima C Stanford</dc:creator>
<dc:creator>Morgana Mongraw-Chaffin</dc:creator>
<dc:creator>Bethany Barone Gibbs</dc:creator>
<dc:creator>Chiadi E Ndumele</dc:creator>
<dc:creator>Chris T Longenecker</dc:creator>
<dc:creator>Misook L Chung</dc:creator>
<dc:creator>Goutham Rao</dc:creator>
<dc:creator>American Heart Association Obesity Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Clinical Cardiology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; and Council on Cardiovascular and Stroke Nursing</dc:creator>
<dc:date>2024-05-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Implementation of Obesity Science Into Clinical Practice: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38766861</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001221</dc:identifier>
</item>
<item>
<title>Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38761800/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>A critical roadblock to HIV vaccine development is the inability to induce B cell lineages of broadly neutralizing antibodies (bnAbs) in humans. In people living with HIV-1, bnAbs take years to develop. The HVTN 133 clinical trial studied a peptide/liposome immunogen targeting B cell lineages of HIV-1 envelope (Env) membrane-proximal external region (MPER) bnAbs (NCT03934541). Here, we report MPER peptide-liposome induction of polyclonal HIV-1 B cell lineages of mature bnAbs and their...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 14:S0092-8674(24)00459-8. doi: 10.1016/j.cell.2024.04.033. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">A critical roadblock to HIV vaccine development is the inability to induce B cell lineages of broadly neutralizing antibodies (bnAbs) in humans. In people living with HIV-1, bnAbs take years to develop. The HVTN 133 clinical trial studied a peptide/liposome immunogen targeting B cell lineages of HIV-1 envelope (Env) membrane-proximal external region (MPER) bnAbs (NCT03934541). Here, we report MPER peptide-liposome induction of polyclonal HIV-1 B cell lineages of mature bnAbs and their precursors, the most potent of which neutralized 15% of global tier 2 HIV-1 strains and 35% of clade B strains with lineage initiation after the second immunization. Neutralization was enhanced by vaccine selection of improbable mutations that increased antibody binding to gp41 and lipids. This study demonstrates proof of concept for rapid vaccine induction of human B cell lineages with heterologous neutralizing activity and selection of antibody improbable mutations and outlines a path for successful HIV-1 vaccine development.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38761800/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38761800</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.033>10.1016/j.cell.2024.04.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38761800</guid>
<pubDate>Sat, 18 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Wilton B Williams</dc:creator>
<dc:creator>S Munir Alam</dc:creator>
<dc:creator>Gilad Ofek</dc:creator>
<dc:creator>Nathaniel Erdmann</dc:creator>
<dc:creator>David C Montefiori</dc:creator>
<dc:creator>Michael S Seaman</dc:creator>
<dc:creator>Kshitij Wagh</dc:creator>
<dc:creator>Bette Korber</dc:creator>
<dc:creator>Robert J Edwards</dc:creator>
<dc:creator>Katayoun Mansouri</dc:creator>
<dc:creator>Amanda Eaton</dc:creator>
<dc:creator>Derek W Cain</dc:creator>
<dc:creator>Mitchell Martin</dc:creator>
<dc:creator>JongIn Hwang</dc:creator>
<dc:creator>Aria Arus-Altuz</dc:creator>
<dc:creator>Xiaozhi Lu</dc:creator>
<dc:creator>Fangping Cai</dc:creator>
<dc:creator>Nolan Jamieson</dc:creator>
<dc:creator>Robert Parks</dc:creator>
<dc:creator>Maggie Barr</dc:creator>
<dc:creator>Andrew Foulger</dc:creator>
<dc:creator>Kara Anasti</dc:creator>
<dc:creator>Parth Patel</dc:creator>
<dc:creator>Salam Sammour</dc:creator>
<dc:creator>Ruth J Parsons</dc:creator>
<dc:creator>Xiao Huang</dc:creator>
<dc:creator>Jared Lindenberger</dc:creator>
<dc:creator>Susan Fetics</dc:creator>
<dc:creator>Katarzyna Janowska</dc:creator>
<dc:creator>Aurelie Niyongabo</dc:creator>
<dc:creator>Benjamin M Janus</dc:creator>
<dc:creator>Anagh Astavans</dc:creator>
<dc:creator>Christopher B Fox</dc:creator>
<dc:creator>Ipsita Mohanty</dc:creator>
<dc:creator>Tyler Evangelous</dc:creator>
<dc:creator>Yue Chen</dc:creator>
<dc:creator>Madison Berry</dc:creator>
<dc:creator>Helene Kirshner</dc:creator>
<dc:creator>Elizabeth Van Itallie</dc:creator>
<dc:creator>Kevin O Saunders</dc:creator>
<dc:creator>Kevin Wiehe</dc:creator>
<dc:creator>Kristen W Cohen</dc:creator>
<dc:creator>M Juliana McElrath</dc:creator>
<dc:creator>Lawrence Corey</dc:creator>
<dc:creator>Priyamvada Acharya</dc:creator>
<dc:creator>Stephen R Walsh</dc:creator>
<dc:creator>Lindsey R Baden</dc:creator>
<dc:creator>Barton F Haynes</dc:creator>
<dc:date>2024-05-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans</dc:title>
<dc:identifier>pmid:38761800</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.033</dc:identifier>
</item>
<item>
<title>OCT-Guided versus Angiography-Guided Coronary Stent Implantation in Complex Lesions: An ILUMIEN IV Substudy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38759907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In complex angiographic lesions, OCT-guided PCI led to a larger MSA and reduced the serious MACE composite of cardiac death, target-vessel MI, or stent thrombosis compared with angiography-guided PCI at 2 years, but did not significantly improve TVF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 6:S0735-1097(24)07085-2. doi: 10.1016/j.jacc.2024.04.037. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: ILUMIEN IV was the first large-scale, multicenter, randomized trial comparing optical coherence tomography (OCT)-guided versus angiography-guided stent implantation in patients with high-risk clinical characteristics and/or complex angiographic lesions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: Here, we aimed to specifically examine outcomes in the complex angiographic lesions subgroup.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: From the original trial population (n=2487), high-risk patients without complex angiographic lesions were excluded (n=514). Complex angiographic lesion characteristics included 1) long or multiple lesions with intended total stent length ≥28 mm; 2) bifurcation lesion with intended two-stent strategy; 3) severely calcified lesion; 4) chronic total occlusion; or 5) in-stent restenosis. The study endpoints were 1) final minimal stent area (MSA); 2) 2-year composite of serious major adverse cardiovascular events (MACE; cardiac death, target-vessel myocardial infarction (MI), or stent thrombosis); and 3) 2-year effectiveness, defined as target-vessel failure (TVF), a composite of cardiac death, target-vessel MI, or ischemia-driven target-vessel revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The post-PCI MSA was larger in the OCT- (n=992) versus angiography-guided (n=981) group (5.56±1.95 versus 5.26±1.81mm<sup>2</sup>; difference, 0.30; 95% confidence interval [CI], 0.14-0.47; P&lt;0.001). Compared with angiography-guided PCI, OCT-guided PCI resulted in a lower risk of serious MACE (3.1% versus 4.9%; hazard ratio [HR], 0.63; 95% CI, 0.40-0.99; P=0.04). TVF was not significantly different between groups (7.3% versus 8.8%; HR, 0.82; 95% CI, 0.59-1.12; P=0.20).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In complex angiographic lesions, OCT-guided PCI led to a larger MSA and reduced the serious MACE composite of cardiac death, target-vessel MI, or stent thrombosis compared with angiography-guided PCI at 2 years, but did not significantly improve TVF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38759907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38759907</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.037>10.1016/j.jacc.2024.04.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38759907</guid>
<pubDate>Fri, 17 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Ziad A Ali</dc:creator>
<dc:creator>Ulf Landmesser</dc:creator>
<dc:creator>Akiko Maehara</dc:creator>
<dc:creator>Doosup Shin</dc:creator>
<dc:creator>Koshiro Sakai</dc:creator>
<dc:creator>Mitsuaki Matsumura</dc:creator>
<dc:creator>Richard A Shlofmitz</dc:creator>
<dc:creator>David Leistner</dc:creator>
<dc:creator>Paolo Canova</dc:creator>
<dc:creator>Fernando Alfonso</dc:creator>
<dc:creator>Franco Fabbiocchi</dc:creator>
<dc:creator>Giulio Guagliumi</dc:creator>
<dc:creator>Matthew J Price</dc:creator>
<dc:creator>Jonathan M Hill</dc:creator>
<dc:creator>Takashi Akasaka</dc:creator>
<dc:creator>Francesco Prati</dc:creator>
<dc:creator>Hiram G Bezerra</dc:creator>
<dc:creator>William Wijns</dc:creator>
<dc:creator>Robert J McGreevy</dc:creator>
<dc:creator>Robert W McNutt</dc:creator>
<dc:creator>Hong Nie</dc:creator>
<dc:creator>Kanitha Phalakornkule</dc:creator>
<dc:creator>Jana Buccola</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>ILUMIEN IV Investigators</dc:creator>
<dc:date>2024-05-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>OCT-Guided versus Angiography-Guided Coronary Stent Implantation in Complex Lesions: An ILUMIEN IV Substudy</dc:title>
<dc:identifier>pmid:38759907</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.037</dc:identifier>
</item>
<item>
<title>Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38759906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Although symptom severity and nature were poorly associated with disease severity, the nature of symptoms powerfully predicted the placebo-controlled efficacy of PCI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 10:S0735-1097(24)06948-1. doi: 10.1016/j.jacc.2024.04.016. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Placebo-controlled evidence from ORBITA-2 found that percutaneous cutaneous intervention (PCI) in stable coronary artery disease with little or no antianginal medication relieved angina, but residual symptoms persisted in many. The reason for this was unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: ; This ORBITA-2 secondary analysis investigates the relationship between presenting symptoms and disease severity (anatomic, non-invasive, and invasive ischemia) and the ability of symptoms to predict the placebo-controlled efficacy of PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Pre-randomization symptom severity and nature were assessed using the ORBITA smartphone application and symptom and quality of life questionnaires including the Rose angina questionnaire. Disease severity was assessed using quantitative coronary angiography (QCA), stress echocardiography, fractional flow reserve (FFR), and instantaneous wave-free ratio (iFR). Bayesian ordinal regression was used.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At pre-randomization, the median number of daily angina episodes was 0.8 (0.4-1.6), 64% had Rose angina, QCA diameter stenosis 61 (49-74), stress echocardiography score 1.0 (0.0-2.7), FFR 0.63 (0.49-0.75), and iFR 0.78 (0.55-0.87). There was little relationship between symptom severity and nature and disease severity: angina symptom score with QCA ordinal correlation coefficient 0.06 (95% CrI 0.00 to 0.08); stress echocardiography 0.09 (95% CrI 0.02 to 0.10); FFR 0.04 (95% CrI -0.03 to 0.07); and iFR 0.04 (95% CrI -0.01 to 0.07). However, Rose angina and guideline-based typical angina were strong predictors of placebo-controlled PCI efficacy (angina symptom score: OR 1.9, 95% CrI 1.6 to 2.1, Pr(Interaction)=99.9% and OR 1.8, 95% CrI 1.6 to 2.1, Pr(Interaction)=99.9%, respectively).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Although symptom severity and nature were poorly associated with disease severity, the nature of symptoms powerfully predicted the placebo-controlled efficacy of PCI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38759906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38759906</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.016>10.1016/j.jacc.2024.04.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38759906</guid>
<pubDate>Fri, 17 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Florentina A Simader</dc:creator>
<dc:creator>Christopher A Rajkumar</dc:creator>
<dc:creator>Michael J Foley</dc:creator>
<dc:creator>Fiyyaz Ahmed-Jushuf</dc:creator>
<dc:creator>Shayna Chotai</dc:creator>
<dc:creator>Nina Bual</dc:creator>
<dc:creator>Arif Khokhar</dc:creator>
<dc:creator>Aisha Gohar</dc:creator>
<dc:creator>Ioannis Lampadakis</dc:creator>
<dc:creator>Sashiananthan Ganesananthan</dc:creator>
<dc:creator>Rachel H Pathimagaraj</dc:creator>
<dc:creator>Alexandra Nowbar</dc:creator>
<dc:creator>John R Davies</dc:creator>
<dc:creator>Tom R Keeble</dc:creator>
<dc:creator>Peter D O'Kane</dc:creator>
<dc:creator>Peter Haworth</dc:creator>
<dc:creator>Helen Routledge</dc:creator>
<dc:creator>Tushar Kotecha</dc:creator>
<dc:creator>James C Spratt</dc:creator>
<dc:creator>Rupert Williams</dc:creator>
<dc:creator>Sukhjinder S Nijjer</dc:creator>
<dc:creator>Sayan Sen</dc:creator>
<dc:creator>Nick Curzen</dc:creator>
<dc:creator>Manas Sinha</dc:creator>
<dc:creator>James P Howard</dc:creator>
<dc:creator>Graham Cole</dc:creator>
<dc:creator>Frank E Harrell</dc:creator>
<dc:creator>Darrel P Francis</dc:creator>
<dc:creator>Matthew J Shun-Shin</dc:creator>
<dc:creator>Rasha K Al-Lamee</dc:creator>
<dc:creator>ORBITA-2 Investigators</dc:creator>
<dc:date>2024-05-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery Disease</dc:title>
<dc:identifier>pmid:38759906</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.016</dc:identifier>
</item>
<item>
<title>Real-world 1-Year Results of Tricuspid Edge-to-Edge Repair from the bRIGHT Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38759905/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240521180807&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Tricuspid TEER using the TriClip system was safe and effective through 1 year for subjects with significant TR and advanced disease in a diverse, real-world population.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 10:S0735-1097(24)07207-3. doi: 10.1016/j.jacc.2024.05.006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Severe tricuspid regurgitation (TR) is known to be associated with poor quality of life and increased risk of death when left untreated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To report the 1-year clinical outcomes of subjects treated by tricuspid transcatheter edge-to-edge repair (TEER) with the TriClip system in a contemporary, real-world setting.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The bRIGHT post-approval study is a prospective, single-arm, open-label, multicenter, post-market registry conducted at 26 sites in Europe with central event adjudication and echocardiographic core-lab assessment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Enrolled subjects were elderly (79±7 years) with significant comorbidities. Eighty-eight percent had baseline massive or torrential TR and 80% percent of subjects were in NYHA class III/ IV. TR was reduced to moderate or less in 81% at 1 year. Significant improvements in NYHA class (21% to 75% I/II, P&lt;0.0001) and KCCQ score (19±26-point improvement, P&lt;0.0001) were observed at 1 year. One-year mortality was significantly lower in subjects who achieved moderate or lower TR at 30 days; however, there was no difference in mortality among subjects that achieved moderate, mild, or trace TR at 30 days. In addition to TR reduction at 30 days, baseline serum creatinine and baseline RV TAPSE were independently associated with mortality at 1 year (OR: 2.169, 95% CI: [1.494, 3.147], P&lt;0.0001; OR: 0.636, 95% CI: [0.415, 0.974], P=0.0375). Mortality was not associated with baseline TR grade, nor with center volume.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Tricuspid TEER using the TriClip system was safe and effective through 1 year for subjects with significant TR and advanced disease in a diverse, real-world population.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38759905/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240521180807&v=2.18.0.post9+e462414">38759905</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.006>10.1016/j.jacc.2024.05.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38759905</guid>
<pubDate>Fri, 17 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Karl-Philipp Rommel</dc:creator>
<dc:creator>Thomas Schmitz</dc:creator>
<dc:creator>Raffi Bekeredjian</dc:creator>
<dc:creator>Georg Nickenig</dc:creator>
<dc:creator>Helge Möllmann</dc:creator>
<dc:creator>Ralph Stephan von Bardeleben</dc:creator>
<dc:creator>Alexander Schmeisser</dc:creator>
<dc:creator>Iskandar Atmowihardjo</dc:creator>
<dc:creator>Rodrigo Estevez-Loureiro</dc:creator>
<dc:creator>Edith Lubos</dc:creator>
<dc:creator>Megan Heitkemper</dc:creator>
<dc:creator>Kelli Peterman</dc:creator>
<dc:creator>Harald Lapp</dc:creator>
<dc:creator>Erwan Donal</dc:creator>
<dc:date>2024-05-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Real-world 1-Year Results of Tricuspid Edge-to-Edge Repair from the bRIGHT Study</dc:title>
<dc:identifier>pmid:38759905</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.006</dc:identifier>
</item>





























</channel>
</rss>